Grail Cancer Blood Test: Trial Shows Promise, But Falls Short of Goal

The promise of early cancer detection through a simple blood test suffered a setback this week as Grail, Inc. Announced topline results from its landmark NHS-Galleri trial. While the test demonstrated a reduction in late-stage cancer diagnoses and a significant increase in the detection of cancers at earlier stages, it did not meet the primary endpoint of statistically significant reduction in Stage III-IV cancers. The news sent shockwaves through the biotech sector, causing Grail’s stock to plummet by more than 50% on Friday, February 20, 2026.

The NHS-Galleri trial, conducted in the United Kingdom, involved over 140,000 participants aged 50 to 77 and aimed to assess the impact of annual multi-cancer screening with the Galleri® test on the National Health Service (NHS). The trial’s design was intended to inform a potential national screening program in England, and the results are also crucial for the ongoing review of Grail’s premarket approval application by the U.S. Food and Drug Administration (FDA). Despite not achieving its primary goal, Grail highlighted a “favorable trend” toward fewer late-stage cancers, particularly within a pre-specified group of 12 deadly cancer types.

The Galleri test, a “liquid biopsy,” analyzes circulating tumor DNA (ctDNA) fragments shed into the bloodstream by cancerous tumors. This approach offers the potential to detect cancer signals even before symptoms manifest, potentially leading to earlier intervention and improved treatment outcomes. The test is designed to identify signals from over 50 different types of cancer. The company reported a four-fold improvement in overall cancer detection rates compared to standard-of-care screening for breast, colorectal, cervical, and high-risk lung cancers when Galleri was added to existing protocols. This suggests a significant enhancement in the ability to identify cancers at an earlier, more treatable stage.

Trial Results: A Mixed Picture for Early Cancer Detection

The primary endpoint of the NHS-Galleri trial – a statistically significant reduction in Stage III-IV cancers – was not met. However, Grail emphasized that a positive trend was observed, particularly in the 12 pre-specified deadly cancer types: cancers of the anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, and stomach. According to Harpal Kumar, president biopharma & Europe at Grail, stage IV diagnoses in these cancers decreased with each year of sequential screening, with a greater than 20% reduction observed in the second and third rounds of screening. He further stated that the test led to a substantial reduction in cancers detected through emergency or unplanned hospital visits, suggesting earlier identification of the disease.

Despite the lack of statistical significance for the primary endpoint, the observed trends are encouraging, according to Grail. The company plans to extend the trial’s follow-up period by six to twelve months to gather additional data and further analyze the results. Detailed findings are expected to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in late May 2026. This extended analysis will be critical in determining the true impact of the Galleri test on cancer outcomes and informing future screening strategies.

Market Reaction and Financial Implications

The announcement of the trial results triggered a significant downturn in Grail’s stock price. Shares opened on Friday, February 20, 2026, at $48.88, a more than 51% decrease from the previous day’s closing price, reflecting investor concerns about the test’s commercial viability. Grail, which became a publicly traded company after spinning off from Illumina in June 2024, had previously reported $136.8 million in Galleri revenue for 2025, a 26% increase compared to the prior year. The company has sold over 185,000 Galleri tests in 2025 and nearly half a million tests since its launch. The financial impact of the trial results remains to be seen, but the company’s future growth trajectory will likely be influenced by its ability to demonstrate the clinical and economic value of the Galleri test.

Regulatory Pathway and Future Prospects

Grail submitted the final portion of its premarket approval (PMA) application to the FDA in late January 2026, based on data from a U.S. Trial involving 25,490 participants and one-year results from the NHS-Galleri trial. FDA approval is considered crucial for broader adoption and securing reimbursement from healthcare payers. A recent legislative change offers a potential pathway for Medicare coverage of approved multi-cancer early detection tests, starting in 2028. President Trump signed into law H.R. 842 in January 2026, authorizing Medicare to cover such tests, a significant step towards wider accessibility.

Despite the trial’s mixed results, access to the Galleri test is expanding. Hims & Hers launched access to Galleri through its platform earlier in February 2026, broadening access to the test for consumers with a prescription. This partnership demonstrates continued interest in multi-cancer early detection and highlights the potential for digital health platforms to play a role in delivering innovative screening solutions. The company continues to emphasize the potential for longer-term benefits with continued screening, suggesting that the impact of the Galleri test may become more pronounced over time.

Understanding Liquid Biopsies and Multi-Cancer Early Detection

Liquid biopsies represent a paradigm shift in cancer detection, moving away from traditional screening methods like mammography or colonoscopy. Instead of imaging or tissue samples, these tests analyze biological fluids, such as blood, for biomarkers indicative of cancer. The Galleri test specifically targets ctDNA, fragments of DNA released by tumor cells into the bloodstream. Detecting these fragments can potentially identify cancer at an earlier stage, when treatment is more likely to be successful. However, it’s essential to note that liquid biopsies are not a replacement for standard screening protocols but rather a complementary tool that may enhance early detection efforts.

The concept of multi-cancer early detection (MCED) aims to identify multiple cancer types simultaneously from a single sample. This approach is particularly appealing due to the fact that many cancers lack effective screening methods, and early detection is often the key to improving outcomes. While the NHS-Galleri trial did not achieve its primary endpoint, it represents a significant step forward in the field of MCED, providing valuable data and insights that will inform future research and development efforts.

Key Takeaways:

• The NHS-Galleri trial did not meet its primary endpoint of statistically significant reduction in Stage III-IV cancers.
• The test demonstrated a reduction in late-stage diagnoses and increased detection of earlier-stage cancers, particularly within a specific group of deadly cancer types.
• Grail plans to extend the trial’s follow-up period to gather additional data.
• The results have had a significant impact on Grail’s stock price.
• FDA approval and Medicare coverage remain crucial for the widespread adoption of the Galleri test.

The future of multi-cancer early detection remains promising, but further research and validation are needed to fully realize its potential. The extended follow-up period of the NHS-Galleri trial and the ongoing review of Grail’s PMA application by the FDA will be critical in shaping the landscape of cancer screening in the years to come. The presentation of detailed results at the ASCO meeting in May 2026 will provide further clarity on the clinical utility of the Galleri test and its potential to improve cancer outcomes.

What are your thoughts on the future of multi-cancer early detection? Share your comments below, and please share this article with your network.